Antibodies by Design™ XmAb® Antibody Therapeutics Corporate Overview August 2020 Forward-Looking Statements Certain statements contained in this presentation, other than statements of historical fact, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Xencor's development plans and timelines; potential regulatory actions; expected use of cash resources; the timing and resu ...

Xencor Inc (NASDAQ:XNCR) Q2 2020 Results Conference Call August 4, 2020 4:30 PM ET Company Participants Charles Liles - Head of Investor Relations Bassil Dahiyat - President and Chief Executive Officer Allen Yang - Chief Medical Officer John Desjarlais - Chief Scientific Officer John Kuch - Chief Financial Officer Conference Call Participants Edward Tenthoff - Piper Sandler & Co. Jonathan Chang - SVB Leerink Mara Goldstein - Mizuho Securities Arlinda Lee - Canaccord Genuity Tom Shrader - BTIG Peter Lawso ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36182 Xencor, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 20-1622502 (State or Other Jurisdiction of Incorporation or Organization) 111 West Lemon Avenue, Monrovia, CA 91016 (Address of Principal Executive Offices) (Zip Code) (626) 305-5900 ☒ QUARTERLY REPORT ...

Xencor, Inc. (NASDAQ:XNCR) Q1 2020 Earnings Conference Call May 7, 2020 4:30 PM ET Company Participants Charles Liles - Associate Director and Head, Corporate Communications and IR Bassil Dahiyat - President and CEO John Kuch - SVP and CFO Allen Yeng - SVP and Chief Medical Officer Conference Call Participants Jonathan Chang - SVB Leerink Arlinda Lee - Canaccord Gabriel Fung - Mizuho Securities Ed Tenthoff - Piper Jaffray Etzer Darout - Guggenheim Securities Operator Ladies and gentlemen, thank you for stan ...

[Special Note Regarding Forward-Looking Statements](index=3&type=section&id=SPECIAL%20NOTE%20REGARDING%20FORWARD%20LOOKING%20STATEMENTS) Forward-looking statements are subject to risks and uncertainties, including COVID-19 impacts, and the company disclaims any obligation to update them - Forward-looking statements are based on current expectations and projections, subject to risks and uncertainties that could cause actual results to differ materially[10](index=10&type=chunk) - Key risk factors include the effects of the COVID-19 pandemic, plans for product candidate development and commercialization, timing of regulatory approvals, estimates for expenses and revenue, competition, and intellectual property position[10](index=10&type=chunk) - The company does not undertake any obligation to update or revise forward-looking statements[12](index=12&type=chunk) [Part I. Financial Information](index=6&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) This part presents Xencor's unaudited interim financial statements, management's discussion, market risk, and controls, detailing financial performance and COVID-19 considerations [Item 1. Financial Statements](index=6&type=section&id=Item%201.%20Financial%20Statements) This section provides unaudited interim financial statements, including Balance Sheets, Statements of Comprehensive Income (Loss), Statement of Stockholders' Equity, Statements of Cash Flows, and detailed notes [Balance Sheets](index=6&type=section&id=Balance%20Sheets%20as%20of%20March%2031%2C%202020%20(unaudited)%20and%20December%2031%2C%202019) Cash and current marketable securities increased, leading to a rise in total current assets, while total assets slightly decreased and liabilities remained stable | Asset/Liability Category | March 31, 2020 (in thousands) | December 31, 2019 (in thousands) | Change (in thousands) | | :----------------------- | :---------------------------- | :------------------------------- | :-------------------- | | Cash and cash equivalents | $73,808 | $50,312 | $23,496 | | Marketable securities (current) | $497,841 | $479,470 | $18,371 | | Total current assets | $588,107 | $558,405 | $29,702 | | Total assets | $666,963 | $670,250 | $(3,287) | | Total current liabilities | $65,917 | $66,558 | $(641) | | Total liabilities | $73,958 | $77,049 | $(3,091) | | Total stockholders' equity | $593,005 | $593,201 | $(196) | [Statements of Comprehensive Income (Loss)](index=7&type=section&id=Statements%20of%20Comprehensive%20Income%20(Loss)%20for%20the%20Three%20Months%20Ended%20March%2031%2C%202020%20and%202019%20(unaudited)) Revenue significantly decreased year-over-year, shifting from net income to a net loss, primarily due to a non-recurring licensing payment in Q1 2019 and increased operating expenses | Metric (in thousands) | Three Months Ended March 31, 2020 | Three Months Ended March 31, 2019 | Change (YoY) | | :-------------------- | :-------------------------------- | :-------------------------------- | :----------- | | Revenue | $32,385 | $111,939 | $(79,554) | | R&D Expenses | $33,943 | $28,183 | $5,760 | | G&A Expenses | $7,219 | $5,512 | $1,707 | | Total Operating Expenses | $41,162 | $33,695 | $7,467 | | Income (loss) from operations | $(8,777) | $78,244 | $(87,021) | | Net income (loss) | $(8,074) | $80,045 | $(88,119) | | Basic EPS | $(0.14) | $1.42 | $(1.56) | | Diluted EPS | $(0.14) | $1.38 | $(1.52) | [Statement of Stockholders' Equity](index=8&type=section&id=Statement%20of%20Stockholders'%20Equity%20for%20the%20Three%20Months%20Ended%20March%2031%2C%202020%20and%202019%20(unaudited)) Total stockholders' equity saw a minor decrease, influenced by a comprehensive loss, while additional paid-in capital increased due to stock award exercises and stock-based compensation | Stockholders' Equity Item (in thousands) | December 31, 2019 | March 31, 2020 | Change | | :--------------------------------------- | :---------------- | :------------- | :----- | | Common Stock (shares) | 56,902,301 | 57,001,253 | 98,952 | | Common Stock (amount) | $569 | $570 | $1 | | Additional Paid-in Capital | $887,873 | $895,855 | $7,982 | | Accumulated Other Comprehensive Income (Loss) | $1,161 | $1,056 | $(105) | | Accumulated Deficit | $(296,402) | $(304,476) | $(8,074) | | Total Stockholders' Equity | $593,201 | $593,005 | $(196) | [Statements of Cash Flows](index=9&type=section&id=Statements%20of%20Cash%20Flows%20for%20the%20Three%20Months%20Ended%20March%2031%2C%202020%20and%202019%20(unaudited)) Cash flow from operating activities significantly improved, shifting from a net use of **$18.7 million** in Q1 2019 to a net provision of **$9.5 million** in Q1 2020, primarily driven by upfront and milestone payments from collaborations, leading to a substantial net increase in cash and cash equivalents | Cash Flow Activity (in thousands) | Three Months Ended March 31, 2020 | Three Months Ended March 31, 2019 | Change (YoY) | | :-------------------------------- | :-------------------------------- | :-------------------------------- | :----------- | | Operating Activities | $9,460 | $(18,728) | $28,188 | | Investing Activities | $12,565 | $13,673 | $(1,108) | | Financing Activities | $1,471 | $667 | $804 | | Net Increase (Decrease) in Cash | $23,496 | $(4,388) | $27,884 | | Cash and cash equivalents, end of period | $73,808 | $21,858 | $51,950 | [Notes to Financial Statements](index=10&type=section&id=Notes%20to%20Financial%20Statements%20(unaudited)) This section details accounting policies, fair value measurements, stock-based compensation, lease obligations, and collaboration agreements, noting no material impact from new accounting standards and the effect of the CARES Act on income taxes - The financial statements are prepared in accordance with U.S. GAAP for interim financial information, including normal recurring adjustments and management estimates[26](index=26&type=chunk) - The company adopted several new accounting pronouncements effective January 1, 2020, none of which had a significant impact on the financial statements[35](index=35&type=chunk)[36](index=36&type=chunk)[37](index=37&type=chunk) Fair Value Hierarchy | Fair Value Hierarchy (in thousands) | March 31, 2020 Total Fair Value | March 31, 2020 Level 1 | March 31, 2020 Level 2 | December 31, 2019 Total Fair Value | December 31, 2019 Level 1 | December 31, 2019 Level 2 | | :---------------------------------- | :------------------------------ | :--------------------- | :--------------------- | :--------------------------------- | :------------------------ | :------------------------ | | Money Market Funds | $49,800 | $49,800 | $— | $32,009 | $32,009 | $— | | Corporate Securities | $332,691 | $— | $332,691 | $281,751 | $— | $281,751 | | Government Securities | $203,382 | $— | $203,382 | $269,245 | $— | $269,245 | | Equity Securities | $2,253 | $2,253 | $— | $— | $— | $— | | Total | $588,126 | $52,053 | $536,073 | $583,005 | $32,009 | $550,996 | [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=35&type=section&id=Item%202.%20Management's%20Discussion%20and%

Xencor, Inc. (NASDAQ:XNCR) Q4 2019 Earnings Conference Call February 24, 2020 4:30 PM ET Corporate Participants Charles Liles - Associate Director and Head, Corporate Communications & Investor Relations Bassil Dahiyat - President and Chief Executive Officer John Kuch - Senior Vice President & Chief Financial Officer Allen Yeng - Chief Medical Officer Conference Call participants Alethia Young - Cantor Fitzgerald Ted Tenthoff - Piper Jaffray Mara Goldstein - Mizuho Gregory Renzo - RBC Capital Markets Arlinda ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36182 Xencor, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation or Or ...

Antibodies by Design™ XmAb® Antibody Therapeutics Corporate Overview November 2019 Forward-Looking Statements Certain statements contained in this presentation, other than statements of historical fact, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Xencor's development plans and timelines; potential regulatory actions; expected use of cash resources; the timing and re ...

Xencor, Inc. (NASDAQ:XNCR) Q3 2019 Earnings Conference Call November 5, 2019 4:30 PM ET Company Participants Charles Liles - Associate Director and Head, Corporate Communications & Investor Relations Bassil Dahiyat - President & Chief Executive Officer John Kuch - Senior Vice President, Finance & Chief Financial Officer Conference Call Participants Alethia Young - Cantor Fitzgerald Etzer Darout - Guggenheim Securities Shanshan Xu - Berenberg Capital Market Mara Goldstein - Mizuho David Ruch - SVB Leerink Ar ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36182 Xencor, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 20-1622502 (State or Other Jurisdiction of Incorporation o ...